Upload
duongtu
View
217
Download
3
Embed Size (px)
Citation preview
Casein Kinase 1 Delta Phosphorylates Tau and Disrupts Its Binding to Microtubules
Guibin Li‡, Haishan Yin§, and Jeff Kuret‡║
From the ‡Center for Molecular Neurobiology; §Ohio State Biochemistry Program, and
║Department of Molecular and Cellular Biochemistry, Ohio State University College of
Medicine and Public Health, Columbus, Ohio 43210
To whom correspondence should be addressed: Jeff Kuret, Ph.D. Center for Neurobiotechnology 1060 Carmack Rd. Columbus, OH 43210 Phone (614) 688-5899 Fax: (614) 292-5379 Email: [email protected] Running title: Tau Phosphorylation by CK1 in situ Keywords: Tau protein, Alzheimer’s disease, microtubules, Tubulin, protein phosphorylation, protein kinase, Casein kinase 1
1
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Abstract
Tau hyperphosphorylation precedes neuritic lesion formation in Alzheimer’s disease, suggesting
it participates in the tau fibrillization reaction pathway. Candidate tau protein kinases include
members of the casein kinase 1 (CK1) family of phosphotransferases, which are highly over-
expressed in Alzheimer’s disease brain and colocalize with neuritic and granulovacuolar lesions.
Here we characterized the contribution of one CK1 isoform, Ckiδ, to the phosphorylation of tau
at residues S202/T205 and S396/S404 in human embryonic kidney-293 cells using immunodetection
and fluorescence microscopy. Treatment of cells with membrane permeable CK1 inhibitor 3-
[(2,3,6-trimethoxyphenyl)methylidenyl]-indolin-2-one (IC261) lowered occupancy of S396/S404
phosphorylation sites by >70% at saturation, suggesting that endogenous CK1 was the major
source of basal phosphorylation activity at these sites. Overexpression of Ckiδ increased CK1
enzyme activity and further raised tau phosphorylation at residues S202/T205 and S396/S404 in situ.
Inhibitor IC261 reversed tau hyperphosphorylation induced by Ckiδ overexpression. Co-
immunoprecipitation assays showed direct association of tau and Ckiδ in situ, consistent with tau
being a Ckiδ substrate. Ckiδ overexpression also produced a decrease in the fraction of bulk tau
bound to detergent-insoluble microtubules. These results suggest that Ckiδ phosphorylates tau at
sites that modulate tau/microtubule binding, and that the expression pattern of Ckiδ in
Alzheimer’s disease is consistent with it playing an important role in tau aggregation.
2
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Introduction
AD1 is a progressive neurodegenerative disease characterized in part by the appearance of
neurofibrillary tangles (NFTs), neuritic plaques, and neuropil threads (1). Each manifestation of
neuritic pathology is comprised of tau protein aggregated into filaments. Because the spatial
distribution of tau fibrillization appears stereotypically, correlates with neuronal cell loss, and
parallels cognitive decline, it is a useful marker of and may contribute to degeneration in AD and
other dementias.
Tau fibrillization is accompanied by extensive phosphorylation on over twenty-five distinct
sites (2,3), some of which function to modulate the ability of tau to bind and stabilize
microtubules (4,5). Candidate enzymes for catalyzing the hyperphosphorylation of tau protein in
disease include members of the CK1 family of protein kinases, which in mammals consist of at
least seven isoforms derived from distinct genes including Ckiα, β, γ1, γ2, γ3, δ and ε (6-10).
Each isoform shares a highly conserved N-terminal catalytic domain (11) with diverse C-
terminal domains of variable lengths. CK1 family members phosphorylate cytoskeletal proteins
such as spectrin, troponin, myosin, ankyrin, tau, and α-synuclein (12-17), but also non-
cytoskeletal proteins such as SV40 T antigen (18), p53 (14,19) and β-catenin (20).
Phosphorylation of these substrates is thought to modulate diverse physiological functions such
as vesicular trafficking, DNA repair, cell cycle progression, and cytokinesis (21).
CK1 levels appear to be regulated within the cell. For example, Ckiδ levels are elevated in
both AD brain (22,23) and the spinal cords of a murine model of amyotropic lateral sclerosis
(24). Moreover, isoforms Ckiα and Ckiδ associate with the neurofibrillary lesions of AD
(25,26), the pathological hallmarks in AD and other tauopathic neurofibrillary degenerations
3
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
diseases. These observations led to the hypothesis that CK1 enzymes regulate tau
phosphorylation in vivo, and that their upregulation in level or activity contributes to tau
hyperphosphorylation in disease (22).
Here we test this hypothesis by examining the ability of one CK1 isoform, Ckiδ, to
phosphorylate tau under basal and overexpression conditions in situ. The data suggests that CK1
activity makes a major contribution to basal levels of tau phosphorylation, and that Ckiδ can
modulate microtubule stability by direct interaction with tau protein.
4
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Experimental Procedures
Materials. Polyclonal antibody against the C-terminus of p35 (C-19) was purchased from Santa
Cruz Biotechnology (Santa Cruz, CA), whereas monoclonal antibodies AT8, Tau5, PHF1, and
128A were obtained from Endogen (Woburn, MA), Dr. L.I. Binder, Northwestern University
Medical School, Dr. Peter Davies, Einstein College of Medicine, and ICOS Corp. (Bothell, WA),
respectively. Monoclonal anti-α-tubulin antibody (27), taxol, and protease inhibitors (1x
complete contained: 1 mM 4-(2-aminoethyl)-bezenesulfonylfluoride, 0.8 µM aprotinin, 40 µM
bestatin, 20 µM leupeptin, 15 µM pepstatin A, 14 µM L-transepoxysuccinyl-leucylamido-[4-
guanidino]butane, and 26 µM N-acetyl-leu-leu-norleu-al) were obtained from Sigma/Aldrich
Chemicals (St. Louis, MO). HEK-293 cells were purchased from ATCC (Manassas, VA),
TransFastTM Transfection Reagent from Promega (Madison, WI), inhibitor IC261 from
CalBiochem (San Diego, CA), and purified bovine brain tubulin from Cytoskeleton (Denver,
CO).
Recombinant Proteins. Recombinant htau40 containing a His6 tag was expressed and purified
as described (28). Poly-His free recombinant htau40 was prepared the same way, except that E.
coli expression was from vector pET-14b (EMD Biosciences, San Diego, CA), and protein
isolated from IMAC was digested 20 h at 4°C with thrombin prior to repetition of IMAC and gel
filtration chromatography.
Human brain Ckiδ cDNA served as template for PCR amplification of C-terminal truncated
Ckiδ (Ckiδ-∆317. The sense primer (5’-ACGGATCCCATATGGAGCTGAGAGTC)
incorporated an NdeI site at the start codon, whereas the downstream primer (5’-
CTCGAGTTAGTGTCTCCAGCCGCTC) contained a TTA stop codon downstream of the
5
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
codon for His317 followed by an XhoI site. The amplified PCR product was subcloned directly
into TOPO2.1 (Invitrogen, Carlsbad, CA) and sequenced in both directions for errors. The Ckiδ-
∆317-TOPO2.1 cDNA was digested with NdeI and XhoI, the approximate 0.9 kb Ckiδ-∆317
fragment was gel purified and subcloned into E. coli expression vector PT7C (28). Recombinant
Ckiδ-∆317 was purified by IMAC and gel filtration chromatography as described previously for
tau protein (28).
Cell Culture, Transfection, and Treatment. cDNAs encoding the longest human tau isoform
(htau40), human Ckiδ, or p25 (an activator of Cdk5) were cloned into the mammalian CMV
expression vector pcDNA3.1 (Invitrogen, Carlsbad, CA). HEK-293 cells, which were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% bovine
serum, 100 U/ml penicillin G, 250 ng/ml amphotericin B, and 100 µg/ml streptomycin (37°C
with 5% CO2), were transiently transfected with these plasmids (5 µg per 60 mm dish) using
TransFastTM reagent according to the manufacturer’s instructions.
To generate a cell line stably expressing human htau40 (stable tau cells), 5 µg of tau-
pcDNA3.1 plasmid was linearized with BglII and transfected into HEK-293 cells. Forty h after
transfection, cells were cultured in selective medium containing 500 µg/ml G418.
To assay CK1 inhibitor IC261, tau stable cells treated with different IC261 concentrations
were harvested after 30, 60, 120, 240, and 480 min of incubation. IC261 was stored as a 50 mM
stock solution in DMSO and diluted to a working stock of 1 mM in H2O before treatment.
To assess toxicity of various treatments, cells were stained with DNA-specific fluorochrome
Hoechst 33258 (Molecular Probes, Eugene, OR) and examined under fluorescence for chromatin
condensation (29). Cells with uniformly distributed chromatin were scored as "viable."
Immunoprecipitation. Cells were harvested and disrupted in Lysis Buffer [20 mM Tris-HCl
6
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
pH 7.4, 140 mM NaCl, 1 mM PMSF, 1 mM Na3NO4, 10 mM NaF, 0.5% (v/v) Nonidet-40, 1
mM EDTA, and 1x complete protease inhibitors], and cell debris was removed by centrifugation
(10 min x 10,000g) at 4oC. Protein concentrations were determined using the Coomassie blue
binding method with bovine serum albumin as standard (30). For immunoprecipitation
experiments, extracts (500 µg) were incubated with 2 µg of each monoclonal antibody examined
(anti-Ckiδ, 128A; anti-tau, Tau5; anti-p25) for 2 h at 4oC. Protein G-agarose beads [60 µl of
25% (w/v) slurry] were then added to the samples and incubation continued for 1 h at 4oC. The
resultant immunocomplexes were collected by centrifugation, washed three times with Lysis
Buffer, and subjected to immunoblot or in vitro protein kinase assays as described below.
Immunoblot Analysis. Aliquots of cell lysates (20 - 40 µg) or immunocomplexes derived from
immunoprecipitation experiments were boiled in SDS-PAGE Loading Buffer (1x buffer
contained 48 mM Tris-HCl, pH 6.8, 7.5% glycerol, 1.8% SDS, and 3.8% 2-mercaptoethanol),
separated by SDS-PAGE, and transferred to polyvinylidene difluoride membranes. After 1 h in
Blocking Buffer (10 mM Tris-Cl, pH 8.0, 150 mM NaCl, pH 8.0, 0.1% Tween-20, 5% nonfat
milk), membranes were incubated with primary antibody for 2 h at room temperature followed
by 1 h with secondary antibody (horseradish peroxidase-conjugated anti-rabbit or anti-mouse
IgG). Immunoreactivity was detected by enhanced chemiluminescence, collected on x-ray film,
and finally quantified on a BioRad GS-800 calibrated laser densitometer.
In Vitro Protein Kinase Assay. Purified protein kinase (Ckiδ-∆317) or immunocomplexes
derived from immunoprecipitation experiments were incubated with 2 µg of htau40 in 20 µl of
Kinase Buffer (50 mM Tris, 200 µM ATP, and 1 mM DTT) at 37°C for up to 4 h. When
necessary, reactions were supplemented with 1.25 µCi [γ-32P]ATP. All reactions were stopped
by addition of 10 µl of 4x SDS-PAGE Loading Buffer. Following SDS-PAGE, gels were
7
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
subjected to immunoblot analysis as described above or stained and dried for autoradiography
using a Molecular Imager FX Pro Plus multi-imager system (BioRad).
RNA Interference. Sequence specific post-transcriptional silencing of selected genes was
initiated by transfection of HEK-293 cells with double stranded RNA oligonucleotides
(synthesized by Dharmacon, Lafayette, CO). Ckiδ/ε isoforms were silenced with RNA duplexes
consisting of oligonucleotides 5’-CUGGGGAAGAAGGGCCdTdT and 5’-
GGUUGCCCUUCCCCAGdTdT (31). RNA duplexes targeting luciferase, a non-mammalian
protein found in fireflies, were used to control for nonspecific effects of siRNA transfection.
These oligonucleotides, termed GL2, consisted of sense (5’-CGU
ACGCGGAAUACUUCGAdTdT) and antisense (5’-UCGAAGUAUUCCGCGUACGdTdT)
components (32). GL2 or Ckiδ/ε siRNA duplexes (5 µg) were transfected into stable tau cells
using TransFastTM reagents for 48 h. Levels of Ckiδ, tau, and phospho-tau were then quantified
by immunoblot analysis performed on cell lysates (30 µg protein) as described above.
Microtubule-Binding Assay. To assay the ability of tau to bind microtubules in situ, HEK-293
cells transfected with pcDNA3.1/tau or Ckiδ/tau for 24 h were harvested in 500 µl Microtubule-
Stabilizing Buffer (80 mM PIPES, pH 6.8, 1 mM GTP, 1 mM MgCl2, 1 mM EGTA, 0.5% Triton
X-100, 30% glycerol, and 1x complete protease inhibitors) in the presence of 10 µM taxol at
37°C. After cell debris was removed by centrifugation (10,000g for 10 min) at 37°C,
supernatant fractions were collected and centrifuged again at 100,000g for 1 h at 35°C (5). The
resultant pellets (P1) were washed twice with and resuspended (500 µl) in Microtubule-
Stabilizing Buffer, sonicated for 10 s, and then subjected along with 100,000g supernatants (S1)
to SDS-PAGE and immunoblot analysis as described above.
To assay the ability of tau to bind microtubules in vitro, tubulin (1 mg/ml) was first
8
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
assembled in Microtubule Assembly Buffer (80 mM PIPES, pH 6.8, 1 mM MgCl2, 1 mM EGTA,
1 mM GTP) containing 10 µM taxol for 30 min at 30°C. Resultant microtubules were then
incubated (37°C for 30 min) with supernatants (S1; 500 µg) from the in situ microtubule binding
assays described above, and then harvested by centrifugation (100,000g for 1 h at 25°C). Pellet
fractions (P2) were resuspended in Microtubule-Assembly Buffer so that their final volumes
equaled those of supernatant fractions (S2). Equal amounts of supernatant (S2) and pellet (P2)
fractions were then analyzed by SDS-PAGE and the distribution of tau protein examined by
immunoblot analysis using monoclonal antibody Tau5.
Cell Extraction and Immunoflorescence Staining. Wild-type HEK-293 cells were cultured on
coverslips for 24 h and transfected with Ckiδ/tau or PcDNA3.1/tau for 24 h as described above.
To extract soluble proteins, cells were washed with PBS and incubated with Microtubule-
Stabilizing Buffer containing 10 µM taxol for 2 min at room temperature. Cells were washed
once with Microtubule-Stabilizing Buffer without detergent. Both the extracted cells and non-
extracted cells were fixed with methanol. Following the PBS washes, cells were sequentially
incubated with PBS containing 3% BSA for 1 h, Tau5 antibody (1:1000) overnight at 4°C, and
fluorescein-labeled goat anti-mouse IgG secondary antibody (1:1000) for 1 h. Immunostaining
was visualized by fluorescence microscopy (Eclipse 800, Nikon, Japan), captured with a SPOT II
digital camera (Diagnostic Instruments, Inc., Sterling Heights, MI), and processed with
Metamorph imaging software (Universal Imaging Corp., Downingtown, PA).
Analytical Methods. Hyperbolic inhibition curves were fit to the rectangular hyperbola:
xb
axy+
=
where y is immunoreactivity determined at inhibitor concentration x, and constant b corresponds
to x at 50% ymax (i.e., IC50).
9
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
10
Probability values were determined by student’s t test for single comparison and one-way
ANOVA with Tukey’s post hoc test for multiple comparisons. All analyses were performed
using the InStat Software program.
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
11
Results
Ckiδ Phosphorylates tau in vitro. To determine whether Ckiδ could directly phosphorylate tau,
a truncated form of the human enzyme (Ckiδ-∆317) was expressed and purified as a His6-fusion
protein and used to phosphorylate tau protein in vitro. Truncated enzyme was used because it
was easily prepared after heterologous expression in E. coli while retaining the protein kinase
activity of full-length protein (33). Incubation of htau40 with purified Ckiδ-∆317 in the presence
of radioactive nucleotide substrate led to detectable phosphate incorporation within 30 min (Fig.
1A). Detection of total tau protein on Western blots using monoclonal antibody Tau5, the
reactivity of which is not phosphorylation dependent (28), revealed a substantial electrophoretic
mobility shift by 4 h incubation (Fig. 1B). These slowly migrating tau species were strongly
labeled by monoclonal antibodies AT8 and PHF1, which selectively bind phospho-tau residues
S202/T205 (34) and S396/S404 (35), respectively. These data show that CK1 isoform Ckiδ could
directly phosphorylate tau protein, and that monoclonal antibodies AT8 and PHF1 could be used
as probes for Ckiδ-mediated phosphorylation reactions.
Ckiδ Phosphorylates tau in situ. To determine whether Ckiδ could modulate tau
phosphorylation in situ, HEK-293 cells were transiently transfected with plasmids encoding
htau40 and either Ckiδ, p25 (an activator of Cdk5), or empty pcDNA vector. Transfection times
of 24 h were employed because cells remained viable during this time frame in all studies
reported herein (data not shown). Cdk5 activator p25 was included because of its ability to
activate endogenous Cdk5 in situ (36) and therefore serve as an alternate source of tau
hyperphosphorylation activity. Total tau protein was detected with monoclonal antibody Tau5
whereas phospho-tau was detected with antibodies AT8 and PHF1. All cells transfected with
htau40 constructs contained detectable levels of tau protein (Fig. 2A). When these cells were co-
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
12
transfected with empty vector (i.e, in the absence of exogenous protein kinase), a portion of total
tau was PHF1 and AT8 positive, reflecting basal levels of tau phosphorylation. Basal levels of
Ckiδ also were substantial in these cells as demonstrated by Western analysis using monoclonal
antibody 128A. However, cotransfection with DNA constructs encoding Ckiδ significantly
increased the amounts of both Ckiδ and phopho-tau detectable by both the AT8 and PHF1
antibodies (Fig. 1A). These data recapitulate the pattern seen in vitro (Fig. 1A) and suggest that
Ckiδ overexpression significantly increased tau phosphorylation in situ (Fig. 2B). Expression of
p25 also induced a large increase tau phosphorylation, primarily owing to the absence of
endogenous p25 in non-transfected cells (Fig. 2B).
To confirm that the increased levels of Ckiδ observed upon overexpression were
accompanied by increases in phosphotransferase activity, Ckiδ was immunoprecipitated and
subjected to in vitro kinase assays using htau40 and [γ-32P]ATP as substrates 24 h after transient
transfection with Ckiδ/tau or pcDNA3.1/tau constructs. Radioactive assay reaction products
were separated by SDS-PAGE, stained with Coomassie blue, and visualized on a
phosphoimager. Although CK1 activity was found in both the Ckiδ/tau overexpressing and
pcDNA3.1/tau control cells (Fig. 3A), quantitation of the data showed that Ckiδ overexpression
led to ~2-fold increases in recoverable phosphotransferase activity (Fig. 3B). These data
confirmed that Ckiδ overexpression lead to increased Ckiδ activity within HEK-293 cells, but
also showed that significant levels of Ckiδ activity were present under basal conditions.
Ckiδ and tau Directly Interact in situ. The Ckiδ-mediated tau phosphorylation observed in
HEK-293 cells could be direct or arise from an indirect protein phosphorylation cascade. To
distinguish these alternatives, tau and Ckiδ were separately immunoprecipitated from stable tau
cells and subjected to Western analysis using monoclonal antibodies 128A or Tau5. Results
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
13
showed that tau and Ckiδ coimmunoprecipitated in both experimental paradigms (Fig. 4C and
D). These data suggest that tau associates with Ckiδ in situ, and therefore potentially serves as a
direct substrate for Ckiδ-mediated phosphorylation reactions.
To determine the region of Ckiδ involved in binding tau protein, htau40 (non His6-tagged)
was incubated with or without truncation mutant Ckiδ-∆317 in vitro and immunoprecipitated
with antibody 128A. Subsequent Western analysis with antibodies 128A and Tau5 confirmed
direct association between truncated Ckiδ and htau40 (Fig. 4B). These data suggest that at least
a portion of the amino acid sequences mediating direct binding of Ckiδ to tau protein are located
in the protein kinase catalytic domain.
CK1 Inhibitor IC261 Reverses Tau Hyperphosphorylation Induced by Ckiδ
Overexpression. IC261 is a small molecule, membrane permeable, ATP-competitive inhibitor
of CK1 isoforms including Ckiδ (14,37). To determine whether inhibitor treatment could
selectively reverse Ckiδ-mediated tau hyperphosphorylation, HEK-293 cells were co-transfected
with Ckiδ/tau, P25/tau, or pcDNA3.1/tau for 24 h, treated with and without IC261 treatment (10
µM for 30 min), and then probed for phospho- and total tau levels with antibodies PHF1, AT8,
and Tau5. The resultant Western blots showed that IC261 inhibited tau phosphorylation induced
by Ckiδ overexpression without affecting expression levels of Ckiδ (Fig. 5A). Inhibition was
selective for CK1, as shown by the failure of IC261 to significantly modulate tau
phosphorylation induced by p25 overexpression (Fig. 5B). These findings are consistent with
the inhibitory selectivity of IC261 determined both in vitro and in situ (37,38), and confirm the
utility of IC261 for inhibition of CK1 activity in culture. Moreover, they suggest that CK1-
mediated tau phosphorylation is opposed by endogenous phosphoprotein phosphatase activity
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
14
that can decrease occupancy of phosphorylation sites in response to IC261 over time courses as
short as 30 min.
Endogenous CK1 contribues to basal levels of tau phosphorylation. The above data showed
that basal levels of both Ckiδ and phospho-tau were substantial in HEK-293 cells expressing tau
protein, and were consistent with previous studies showing that phosphorylation sites S396 and
S202 were partially occupied in both stable and transiently transfected 3T3, CHO, and SH-SY5Y
cells (39-41). To assess the contribution of endogenous Ckiδ activity to basal levels of tau
phosphorylation, an HEK-293 cell line stably expressing htau40 was generated and employed in
two experimental approaches. First, the dependence of tau phosphorylation on activity
contributed by all CK1 isoforms was estimated by treating stable tau-HEK-293 cells with
varying concentrations of IC261. In the absence of inhibitor, significant amounts of tau were
detectable in this cell line, with a portion being PHF1 reactive (Fig. 6A). Although addition of
IC261 for 30 min did not change total tau levels (i.e., detectable with antibody Tau5), it did
result in large decreases in levels of phospho-tau detected by antibody PHF1 (Fig. 6A).
Inhibition of tau phosphorylation was dose dependent, with an IC50 of 1.5 ± 0.5 µM and up to
71.9 ± 7.5% of PHF1 reactivity at saturation (Fig. 6B). In vitro, IC261 has been shown to inhibit
purified recombinant Ckiδ with an IC50 of 1.1 ± 0.1 µM and 98.1 ± 3.2% of activity at saturation
(Fig. 6B; data replotted from Fig. 1 of Ref. 37). These data suggest that CK1 activity makes a
major contribution to basal levels of tau phosphorylation in HEK-293 cells.
As a second approach, the specific contribution of CK1 isoforms Ckiδ/ε to basal tau
phosphorylation was assessed by siRNA-mediated downregulation conducted 48 h after
transfection. RNA interference promotes hydrolysis of targeted mRNA in a sequence-specific
reaction (42,43). The levels of total tau, phosphorylated tau and Ckiδ were then detected by
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
15
immunoblot analysis as a negative control, siRNA oligonucleotides selective for luciferase
(GL2) were employed. Compared to GL2 treatment, Ckiδ/ε siRNA lowered Ckiδ levels ~30%
48 h after transfection and decreased phosphorylated tau about 25% as well (Fig. 7B). RNA
interference did not change the expression levels of total tau (Fig. 7A). These data indicate that
either downregulating Ckiδ activity or its protein level decreases tau phosphorylation, and
suggests that Ckiδ/ε contributes at least a portion of the basal CK1 activity detectable in HEK-
293 cells.
Ckiδ-mediated Tau Phosphorylation Disrupts Microtubule Binding. The microtubule-
binding activity of tau protein is modulated by phosphorylation (4,5). To assess the effect of
Ckiδ-induced phosphorylation on tau/tubulin interactions, HEK-293 cells transiently co-
transfected with Ckiδ/tau or pcDNA/tau constructs were examined by fluorescence microscopy
after extraction with detergent in the presence of taxol (a microtubule stabilizing agent). In the
absence of extraction, total tau immunofluorescence in both Ckiδ/tau or pcDNA/tau transfections
were similar, again demonstrating that Ckiδ overexpression did not markedly change tau levels
over the time course of the experiment (Fig. 8A). But in detergent extracted cells, which
retained a detergent-insoluble cytoskeleton, levels of tau immunofluorescence were significantly
lower in the presence of Ckiδ (Ckiδ/tau transfection) than in its absence (pcDNA/tau
transfection). These data suggested that the fraction of detergent-stable (i.e., microtubule-
associated) tau decreased in response to phosphorylation induced by Ckiδ overexpression.
To confirm these findings, HEK-293 cells transiently co-transfected with Ckiδ/tau or
pcDNA/tau for 24 h were detergent extracted, fractionated into soluble (S1) and particulate (P1)
fractions (the latter containing microtubules), and subjected to Western analysis using antibodies
Tau5 and PHF1. Phospho-tau (detected by PHF1) was found exclusively in the soluble fraction,
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
16
with greater amounts recovered from cells transfected with Ckiδ/tau than with pcDNA/tau (Fig.
8B). In contrast, significant amounts of total tau (detected by Tau5) were recovered in both
particulate and soluble fractions (Fig. 8B). However, the subcellular distribution of total tau
shifted toward the soluble pool in cells transfected with Ckiδ/tau compared to pcDNA/tau cells
(Fig. 8C).
Together these data suggest that the microtubule-binding activity of tau decreases in response
to Ckiδ-mediated phosphorylation. To test this hypothesis, soluble tau prepared from each of the
cell populations described above (fraction S1) was subjected to in vitro microtubule binding
assays. Results showed that a portion of soluble tau from pcDNA/tau cells retained an ability to
associate with synthetic microtubules (Fig. 8D), consistent with tau overexpression leading to
saturation of endogenous microtubules. In contrast, soluble tau prepared from Ckiδ/tau cells was
almost devoid of microtubule-binding activity (Fig. 8D), despite accumulating to higher levels
than in control extracts (Fig. 8C,D). These data suggest that the accumulation of soluble tau
observed in situ upon Ckiδ-overpression results from phosphorylation of tau protein at sites that
directly modulate microtubule binding.
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
17
Discussion
CK1 Isozymes and tau Phosphorylation. Owing to its natively unfolded structure and high
complement of hydroxyamino acids, tau is an efficient substrate for many protein kinases in vitro
(44), including tissue-derived CK1 activity (13,16). Here it was found that CK1 serves as a tau
protein kinase in situ as well. First, studies with selective inhibitor IC261 showed that over 70%
of basal tau phosphorylation at S396/S404 sites in HEK-293 cells stems from CK1 activity.
Supporting this conclusion, the IC50 for IC261 in situ was only slightly higher than the value
determined in vitro with purified Ckiδ. Moreover, the IC261 inhibition isotherm was consistent
with a single class of binding site. Because IC261 inhibits most CK1 isoforms with similar
potency (37), basal levels of tau phosphorylation could potentially result from the activity of
multiple CK1 isoforms. But the decrease in phospho-tau accompanying downregulation of
Ckiδ/ε using RNA interference suggests that these specific isoforms compose at least a portion
of IC261-sensitive tau phosphorylation activity under basal conditions. Indeed, Ckiδ and tau
could be co-immunoprecipitated from stable tau cells containing only basal levels of Ckiδ.
These data demonstrate that tau and Ckiδ directly associate in situ, and are consistent with their
colocalization to microtubules (16).
Second, overexpression of Ckiδ increased tau phosphorylation at sites it phosphorylated in
vitro. Again, IC261 totally reversed the tau hyperphosphorylation induced by Ckiδ
overexpression. However, the recognition sequence mediating the substrate selectivity of Ckiδ is
not understood in the context of tau phosphorylation. On the basis of studies with short peptides,
CK1 isoforms are phosphotropic kinases that recognize the motif S/T(P)XXS/T (45,46).
Nonetheless, priming of substrates with phosphate is not a strict requirement, and motifs
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
18
consisting of acidic residues N- or C-terminal to the phosphorylatable residue also are
phosphorylated by CK1 (20,47,48). Although our in vitro data showing that Ckiδ
phosphorylated recombinant tau at S202/T205 and S396/S404 is consistent with a previous study
showing that tissue-derived CK1 activity phosphorylates tau at T231, S396/S404 (17), the
relationship between these sites and the motifs summarized above is weakly apparent only for
S396/S404. It appears that recognition of full-length tau as substrate differs from that of short
peptides. In any event, phosphorylation of tau at S202/S205 and S396/S404 by Ckiδ does not require
priming by other protein kinases.
Consequences of CK1-mediated tau Phosphorylation. Tau protein binds and stabilizes
microtubules (49). However, this microtubule stabilizing function is regulated by its
phosphorylation state. For example, hyperphosphorylated tau from AD brain binds to
microtubules weakly (50,51), but strong binding can be restored after dephosphorylation (4).
Thus, the stability of the axonal cytoskeleton may be influenced the equilibrium between tau
phosphorylation and dephosphorylation. Phosphorylation sites that mediate this activity include
S199, S202, S231, T205, S396, and S404 (5,52). Ckiδ phosphorylates most of these sites in situ, and as
a result tau/microtubule equilibrium shifts markedly toward free tau in response to Ckiδ
overexpression. Similar shifts have been observed following Cdk5/p25, GSK3β, or PKA
induced phosphorylation of tau (5,36,53-56). Moreover, Cdk5/p39-induced tau phosphorylation
reduces its affinity for microtubules during development in a transgenic mouse model (57).
These data suggest that control of microtubule stability may involve common phosphorylation
sites that are differentially regulated through the action of multiple protein kinases.
Role of tau Phosphorylation in Disease. The pathway through which tau fibrillizes in disease
is not entirely clear but appears to begin with amorphous aggregation of tau protein into non-
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
19
fibrillar deposits (58). Phosphorylation can play a major role in this process, by modulating the
equilibrium between microtubule-bound and free populations as discussed above. In vitro,
elevated concentrations of phospho-tau promotes amorphous aggregation (59). In vivo,
amorphous deposits, frequently in conjunction with intracellular membranes, are where the
earliest beta-sheet enriched species are detectable using fluorescent dyes (60). Studies with
synthetic inducers of tau fibrillization have revealed the existence of a partially folded, thioflavin
S-positive intermediate in the reaction pathway, the formation of which appears to be essential
for fibrillization (61). Therefore, the key roles of tau phosphorylation in early stage disease
appear to be modulation of the tau/microtubule equilibrium to raise intracellular concentrations
of free tau, and promotion of amorphous aggregation from which assembly competent
intermediates can form. Consistent with this model, extensive hyperphosphorylation of tau in
COS cells leads to thioflavin-S positive deposits that are not fibrillar in appearance and contain
only modest amounts of tau filaments (40).
CK1 in Disease. The properties of CK1 isoforms are consistent with a role in disease. First, as
shown here, CK1 composes the bulk of basal tau phosphorylation activity in HEK-293 cells, and
phosphorylates tau on sites that modulate tau function. These observations are consistent with
Ckiδ and tau being resident on microtubules (16). Second, CK1 isoforms correlate spatially with
neurofibrillary lesions in both AD (22) and other tauopathies (26), and appear as major
components in preparations of authentic, disease-derived filaments (25). One isoform, Ckiδ, is a
particularly robust marker of granulovacuolar degeneration bodies (22). Thus CK1 is associated
with more than one lesion in AD. Third, the appearance of CK1-positive lesions correlates
temporally with memory decline in longitudinal studies of AD, suggesting that CK1 is as
powerful a marker of AD progression as is tau (62). Finally, levels of at least one CK1 isoform,
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
20
Ckiδ, are greatly increased in postmortem AD tissue (22). Unlike tau protein, overexpression of
Ckiδ is observable at the mRNA level (23), suggesting that accumulation does not result solely
from sequestration with insoluble proteinaceous inclusions. In situ, Ckiδ expression increases in
response to drug- or γ-irradiation- induced genotoxic stress suggesting DNA damage as a
potential mechanism for the elevated levels seen in AD (19,63). Further study of Ckiδ
expression in AD will be required to clarify this issue.
Despite these properties, CK1 is but one of several protein kinases capable of
phosphorylating tau in situ. GSK3β and Cdk5 also physically associate with tau within cells (64)
and can modulate tau phosphorylation in transgenic animal models (65,66). GSK3β most
prominently catalyzes phosphorylation at S202, S235, S396, S404 (55), whereas Cdk5/p25 has been
shown to phosphorylate tau at T181, S202, T205, T212, T217, S396, and S404 (54,67,68). Thus GSK3β
and Cdk5/p25 potentially join CK1 in modulating tau/microtubule equilibrium (69). Although
the potential interplay among these enzymes is unknown, it is interesting to note that GSK3β
functions primarily as a phosphate-directed protein kinase dependent on priming of substrates by
other protein kinases (70). Because of its strong contribution to basal tau phosphorylation state
and inducibility in response to stress, CK1 could potentially provide priming activity as it does
with β-catenin phosphorylation (71). Yet CK1 also recognizes primed substrates as in the case
of p53 (72), and in this substrate recognition mode could potentially further amplify disease-
associated phosphorylation of sites found tightly clustered around the microtubule repeat region
(2,3).
Finally, we note that CK1 phosphorylates proteins in addition to tau in vivo. In the cases of
p53 (72), β-catenin (73), multidrug transporter Pdr5p (74), Hedgehog signaling effector Cubitus
interruptus (75), and proteins involved in circadian rhythm control (76), CK1-mediated
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
21
phosphorylation modulates protein turnover. This function may be part of the neuronal response
to stress, accounting for both the induction of CK1 in AD and its presence in granulovacuolar
degeneration bodies. Thus CK1-mediated tau phosphorylation may result from an attempt by the
cell to modulate protein turnover in response to cellular distress.
Acknowledgments
The authors thank Dr. Rick Dobrowsky, University of Kansas, for providing the p25-pCDNA
construct, Dr. Peter Davies, Albert Einstein College of Medicine, for providing PHF1 antibody,
and Dr. Lester I. Binder for providing monoclonal antibody Tau5.
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
22
References
1. Buee, L., Bussiere, T., Buee-Scherrer, V., Delacourte, A., and Hof, P. R. (2000) Brain
Res. Brain Res. Rev. 33, 95-130
2. Hanger, D. P., Betts, J. C., Loviny, T. L., Blackstock, W. P., and Anderton, B. H. (1998)
J. Neurochem. 71, 2465-2476
3. Morishima-Kawashima, M., Hasegawa, M., Takio, K., Suzuki, M., Yoshida, H.,
Watanabe, A., Titani, K., and Ihara, Y. (1995) Neurobiol. Aging 16, 365-371; discussion
371-380
4. Bramblett, G. T., Goedert, M., Jakes, R., Merrick, S. E., Trojanowski, J. Q., and Lee, V.
M. (1993) Neuron 10, 1089-1099
5. Wagner, U., Utton, M., Gallo, J., and Miller, C. (1996) J. Cell Sci. 109, 1537-1543
6. Fish, K. J., Cegielska, A., Getman, M. E., Landes, G. M., and Virshup, D. M. (1995) J.
Biol. Chem. 270, 14875-14883
7. Graves, P., Haas, D., Hagedorn, C., DePaoli-Roach, A., and Roach, P. (1993) J. Biol.
Chem. 268, 6394-6401
8. Rowles, J., Slaughter, C., Moomaw, C., Hsu, J., and Cobb, M. H. (1991) Proc. Natl.
Acad. Sci. U.S.A. 88, 9548-9552
9. Zhai, L., Graves, P. R., Robinson, L. C., Italiano, M., Culbertson, M. R., Rowles, J.,
Cobb, M. H., DePaoli-Roach, A. A., and Roach, P. J. (1995) J. Biol. Chem. 270, 12717-
12724
10. Kitabayashi, A. N., Kusuda, J., Hirai, M., and Hashimoto, K. (1997) Genomics 46, 133-
137
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
23
11. Xu, R. M., Carmel, G., Sweet, R. M., Kuret, J., and Cheng, X. (1995) EMBO J. 14, 1015-
1023
12. Simkowski, K., and Tao, M. (1980) J. Biol. Chem. 255, 6456-6461
13. Singh, T., Grundke-Iqbal, I., and Iqbal, K. (1995) J. Neurochem. 64, 1420-1423
14. Behrend, L., Milne, D. M., Stoter, M., Deppert, W., Campbell, L. E., Meek, D. W., and
Knippschild, U. (2000) Oncogene 19, 5303-5313
15. Okochi, M., Walter, J., Koyama, A., Nakajo, S., Baba, M., Iwatsubo, T., Meijer, L.,
Kahle, P. J., and Haass, C. (2000) J. Biol. Chem. 275, 390-397
16. Behrend, L., Stoter, M., Kurth, M., Rutter, G., Heukeshoven, J., Deppert, W., and
Knippschild, U. (2000) Eur. J. Cell Biol. 79, 240-251
17. Singh, T. J., Zaidi, T., Grundke-Iqbal, I., and Iqbal, K. (1996) Mol. Cell. Biochem. 154,
143-151
18. Cegielska, A., Gietzen, K. F., Rivers, A., and Virshup, D. M. (1998) J. Biol. Chem. 273,
1357-1364
19. Knippschild, U., Milne, D. M., Campbell, L. E., DeMaggio, A. J., Christenson, E.,
Hoekstra, M. F., and Meek, D. W. (1997) Oncogene 15, 1727-1736
20. Marin, O., Bustos, V. H., Cesaro, L., Meggio, F., Pagano, M. A., Antonelli, M., Allende,
C. C., Pinna, L. A., and Allende, J. E. (2003) Proc. Natl. Acad. Sci. U.S.A. 100, 10193-
10200
21. Gross, S., Simerly, C., Schatten, G., and Anderson, R. (1997) J. Cell Sci. 110, 3083-3090
22. Ghoshal, N., Smiley, J. F., DeMaggio, A. J., Hoekstra, M. F., Cochran, E. J., Binder, L.
I., and Kuret, J. (1999) Am. J. Pathol. 155, 1163-1172
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
24
23. Yasojima, K., Kuret, J., DeMaggio, A. J., McGeer, E., and McGeer, P. L. (2000) Brain
Res. 865, 116-120
24. Hu, J. H., Chernoff, K., Pelech, S., and Krieger, C. (2003) J. Neurochem. 85, 422-431
25. Kuret, J., Johnson, G. S., Cha, D., Christenson, E. R., DeMaggio, A. J., and Hoekstra, M.
F. (1997) J. Neurochem. 69, 2506-2515
26. Schwab, C., DeMaggio, A. J., Ghoshal, N., Binder, L. I., Kuret, J., and McGeer, P. L.
(2000) Neurobiol. Aging 21, 503-510
27. Blose, S. H., Meltzer, D. I., and Feramisco, J. R. (1984) J. Cell Biol. 98, 847-858
28. Carmel, G., Mager, E. M., Binder, L. I., and Kuret, J. (1996) J. Biol. Chem. 271, 32789-
32795
29. McGinty, A., Chang, Y. W., Sorokin, A., Bokemeyer, D., and Dunn, M. J. (2000) J. Biol.
Chem. 275, 12095-12101
30. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254
31. Eide, E. J., Vielhaber, E. L., Hinz, W. A., and Virshup, D. M. (2002) J. Biol. Chem. 277,
17248-17254
32. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T.
(2001) Nature 411, 494-498
33. Graves, P. R., and Roach, P. J. (1995) J. Biol. Chem. 270, 21689-21694
34. Goedert, M., Jakes, R., and Vanmechelen, E. (1995) Neurosci. Lett. 189, 167-169
35. Otvos, L., Jr., Feiner, L., Lang, E., Szendrei, G. I., Goedert, M., and Lee, V. M. (1994) J.
Neurosci. Res. 39, 669-673
36. Patrick, G. N., Zukerberg, L., Nikolic, M., de la Monte, S., Dikkes, P., and Tsai, L. H.
(1999) Nature 402, 615-622
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
25
37. Mashhoon, N., DeMaggio, A. J., Tereshko, V., Bergmeier, S. C., Egli, M., Hoekstra, M.
F., and Kuret, J. (2000) J. Biol. Chem. 275, 20052-20060
38. Liu, F., Ma, X.-H., Ule, J., Bibb, J. A., Nishi, A., DeMaggio, A. J., Yan, Z., Nairn, A. C.,
and Greengard, P. (2001) PNAS 98, 11062-11068
39. Hamdane, M., Sambo, A. V., Delobel, P., Begard, S., Violleau, A., Delacourte, A.,
Bertrand, P., Benavides, J., and Buee, L. (2003) J. Biol. Chem. 278, 34026-34034
40. Sato, S., Tatebayashi, Y., Akagi, T., Chui, D. H., Murayama, M., Miyasaka, T., Planel,
E., Tanemura, K., Sun, X., Hashikawa, T., Yoshioka, K., Ishiguro, K., and Takashima, A.
(2002) J. Biol. Chem. 277, 42060-42065
41. Sygowski, L. A., Fieles, A. W., Lo, M. M., Scott, C. W., and Caputo, C. B. (1993) Brain
Res. Mol. Brain Res. 20, 221-228
42. Vickers, T. A., Koo, S., Bennett, C. F., Crooke, S. T., Dean, N. M., and Baker, B. F.
(2003) J. Biol. Chem. 278, 7108-7118
43. Elbashir, S. M., Lendeckel, W., and Tuschl, T. (2001) Genes Dev. 15, 188-200
44. Mandelkow, E. M., Biernat, J., Drewes, G., Gustke, N., Trinczek, B., and Mandelkow, E.
(1995) Neurobiol. Aging 16, 355-362; discussion 362-353
45. Flotow, H., Graves, P. R., Wang, A. Q., Fiol, C. J., Roeske, R. W., and Roach, P. J.
(1990) J. Biol. Chem. 265, 14264-14269
46. Flotow, H., and Roach, P. J. (1991) J. Biol. Chem. 266, 3724-3727
47. Marin, O., Meggio, F., and Pinna, L. A. (1994) Biochem. Biophys. Res. Comm. 198, 898-
905
48. Pulgar, V., Marin, O., Meggio, F., Allende, C. C., Allende, J. E., and Pinna, L. A. (1999)
Eur. J. Biochem. 260, 520-526
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
26
49. Goedert, M. (1993) Trends Neurosci. 16, 460-465
50. Busciglio, J., Lorenzo, A., Yeh, J., and Yankner, B. A. (1995) Neuron 14, 879-888
51. Sontag, E., Nunbhakdi-Craig, V., Bloom, G. S., and Mumby, M. C. (1995) J. Cell Biol.
128, 1131-1144
52. Sontag, E., Nunbhakdi-Craig, V., Lee, G., Bloom, G. S., and Mumby, M. C. (1996)
Neuron 17, 1201-1207
53. Wada, Y., Ishiguro, K., Itoh, T. J., Uchida, T., Hotani, H., Saito, T., Kishimoto, T., and
Hisanaga, S. (1998) J. Biochem. (Tokyo) 124, 738-746
54. Evans, D. B., Rank, K. B., Bhattacharya, K., Thomsen, D. R., Gurney, M. E., and
Sharma, S. K. (2000) J. Biol. Chem. 275, 24977-24983
55. Utton, M. A., Vandecandelaere, A., Wagner, U., Reynolds, C. H., Gibb, G. M., Miller, C.
C., Bayley, P. M., and Anderton, B. H. (1997) Biochem. J. 323, 741-747
56. Scott, C., Spreen, R., Herman, J., Chow, F., Davison, M., Young, J., and Caputo, C.
(1993) J. Biol. Chem. 268, 1166-1173
57. Takahashi, S., Saito, T., Hisanaga, S.-i., Pant, H. C., and Kulkarni, A. B. (2003) J. Biol.
Chem. 278, 10506-10515
58. Bancher, C., Brunner, C., Lassmann, H., Budka, H., Jellinger, K., Wiche, G.,
Seitelberger, F., Grundke-Iqbal, I., Iqbal, K., and Wisniewski, H. M. (1989) Brain Res.
477, 90-99
59. Alonso, A. C., Grundke-Iqbal, I., and Iqbal, K. (1996) Nat. Med. 2, 783-787
60. Galvan, M., David, J. P., Delacourte, A., Luna, J., and Mena, R. (2001) J. Alzheimers
Dis. 3, 417-425
61. Chirita, C. N., and Kuret, J. (2004) Biochemistry 43, in press
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
27
62. Ghoshal, N., Garcia-Sierra, F., Wuu, J., Leurgans, S., Bennett, D. A., Berry, R. W., and
Binder, L. I. (2002) Exp. Neurol. 177, 475-493
63. Knippschild, U., Milne, D., Campbell, L., and Meek, D. (1996) Oncogene 13, 1387-1393
64. Sun, W., Qureshi, H. Y., Cafferty, P. W., Sobue, K., Agarwal-Mawal, A., Neufield, K.
D., and Paudel, H. K. (2002) J. Biol. Chem. 277, 11933-11940
65. Lucas, J. J., Hernandez, F., Gomez-Ramos, P., Moran, M. A., Hen, R., and Avila, J.
(2001) EMBO J. 20, 27-39
66. Spittaels, K., Van den Haute, C., Van Dorpe, J., Geerts, H., Mercken, M., Bruynseels, K.,
Lasrado, R., Vandezande, K., Laenen, I., Boon, T., Van Lint, J., Vandenheede, J.,
Moechars, D., Loos, R., and Van Leuven, F. (2000) J. Biol. Chem. 275, 41340-41349
67. Lund, E. T., McKenna, R., Evans, D. B., Sharma, S. K., and Mathews, W. R. (2001) J.
Neurochem. 76, 1221-1232
68. Hashiguchi, M., Sobue, K., and Paudel, H. K. (2000) J. Biol. Chem. 275, 25247-25254
69. Cho, J. H., and Johnson, G. V. (2003) J. Biol. Chem. 278, 187-193
70. Harwood, A. J. (2001) Cell 105, 821-824
71. Amit, S., Hatzubai, A., Birman, Y., Andersen, J. S., Ben-Shushan, E., Mann, M., Ben-
Neriah, Y., and Alkalay, I. (2002) Genes Dev. 16, 1066-1076
72. Sakaguchi, K., Saito, S., Higashimoto, Y., Roy, S., Anderson, C. W., and Appella, E.
(2000) J. Biol. Chem. 275, 9278-9283
73. Gao, Z. H., Seeling, J. M., Hill, V., Yochum, A., and Virshup, D. M. (2002) Proc. Natl.
Acad. Sci. U.S.A. 99, 1182-1187
74. Decottignies, A., Owsianik, G., and Ghislain, M. (1999) J. Biol. Chem. 274, 37139-37146
75. Price, M. A., and Kalderon, D. (2002) Cell 108, 823-835
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
28
76. Kloss, B., Price, J. L., Saez, L., Blau, J., Rothenfluh, A., Wesley, C. S., and Young, M.
W. (1998) Cell 94, 97-107
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
29
Footnotes
*This work was supported by National Institutes of Health grant AG14452 (to J.K.)
1The abbreviations used are: AD, Alzheimer's disease; Cdk5, cyclin-dependent kinase 5; CK1,
casein kinase 1; Ckiδ-∆317, C-terminal truncated Ckiδ; DMSO, dimethyl sulfoxide; GSK3β,
glycogen synthase kinase-3β; his6, polyhistidine tag; HEK, human embryonic kidney; IC261, 3-
[(2,3,6-trimethoxyphenyl)methylidenyl]-indolin-2-one; IMAC, immobilized metal affinity
chromatography; siRNA, small interfering RNA.
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
30
Figure legends
Fig. 1. Ckiδ phosphorylates tau at S202, T205, S396, and S404 in vitro. Recombinant His6-tagged
htau40 (0.2 mg/ml) was incubated in the presence or absence of Ckiδ-∆317 (50 ng) under
phosphorylating conditions and subjected to SDS-PAGE and Western analysis. A, after 30 min
at 37°C in the presence of [γ-32P]ATP, phospho-tau could be detected by phosphorimaging.
However, total tau as detected by Coomassie blue (CB) staining of SDS gels shows essentially
no band shift. The bottom panel shows Ckiδ-∆317 detected with monoclonal antibody 128A
antibody. B, after 4 h at 37°C, total tau as detected with monoclonal antibody Tau5 shows a
marked band shift. Phospho-tau species were detected by monoclonal antibodies PHF1 and
AT8, suggesting that, at a minimum, Ckiδ-∆317 phosphorylated sites S202, T205, S396, and S404 on
htau40.
Fig. 2. Ckiδ induces tau phosphorylation in situ. HEK-293 cells transiently co-transfected
(24 h) with p25/tau, Ckiδ/tau, and empty pcDNA vector/tau were harvested, lysed, and subjected
to immunoblot analysis using monoclonal antibodies AT8, PHF1, Tau5, 128A, or C-19. A, cells
transfected with empty vector showed measurable basal levels of phospho-tau and Ckiδ but not
of p25. Transfection of cells with Ckiδ or cdk5 activator p25 significantly increased phospho-
tau over basal levels. B, total tau (Tau5 epitope) and phospho-tau (PHF1 epitope) levels were
quantified densitometrically from three individual experiments. When normalized for total tau
content, phospho-tau was found to increase significantly with both p25 and Ckiδ transfection. *,
p < 0.01; **, p < 0.001 when compared to empty vector control.
Fig. 3. In vitro kinase assay. HEK-293 cells transiently transfected (24 h) with Ckiδ/tau or
empty vector/tau were harvested, lysed, and subjected to immunoprecipitation assays using anti-
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
31
Ckiδ antibody 128A. Ckiδ immunocomplexes from Ckiδ/tau (lane 1) or from empty vector/tau
(lane 2) were then incubated in vitro with His6-htau40 and [γ-32P]ATP for 30 min and subjected
to SDS-PAGE. A, phospho-tau detected by phosphorimaging shows that transfection with Ckiδ
increased immunoprecipitable Ckiδ activity (32P), which correlated with levels of Ckiδ protein
(128A). Bottom panel shows total tau detected by Coomassie blue staining. B, quantitative data
from three independent experiments presented as mean ± S.E. **, p < 0.001 compared with
empty vector control.
Fig. 4. Ckiδ associates with tau in situ. Lysates (Lys) prepared from stable tau or wild-type
HEK-293 cells were immunoprecipitated with anti-tau (Tau5) or anti-Ckiδ (128A) monoclonal
antibodies as described in Experimental Procedures and subjected to immunoblot analysis using
A, 128A or B, Tau5 as probes. A, both wild-type and stable tau cells contained Ckiδ that could
be immunoprecipitated with 128A. B, in contrast, only stable tau cells contained detectable tau
protein after immunoprecipitation with Tau5. Ckiδ and tau coimmunoprecipitated with either
128A or Tau5 antibodies in stable tau cells, suggesting direct association in situ. C, htau40 (1
µg/ml) without His6 tag incubated (4°C overnight) with or without truncation mutant Ckiδ-∆317
(1 µg/ml) in Lysis Buffer was immunoprecipitated with antibodies Tau5 or 128A and subjected
to immunoblot analysis with anti-tau (Tau5) and anti-Ckiδ (128A) antibodies. Tau and Ckiδ-
∆317 coimmunoprecipitated under these conditions, suggesting direct interaction between tau
and the catalytic domain of Ckiδ in vitro.
Fig. 5. IC261 inhibits tau phosphorylation induced by Ckiδ. HEK-293 cells transiently
transfected (24 h) with tau/p25, tau/Ckiδ, or empty vector/tau were treated with either 10 µM
IC261(IC), or vehicle control (Con) for an additional 30 min. Cell lysates were then prepared
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
32
and subjected to SDS-PAGE (30 µg/lane). A, representative immunoblots using monoclonal
antibodies AT8, PHF1 Tau5, 128A, and C-19 show that IC261 inhibited basal and Ckiδ-induced
tau phosphorylation without modulating the levels of total tau or Ckiδ. In contrast, neither p25
levels nor p25-induced tau phosphorylation was significantly affected by IC261. B, phospho-tau
levels were quantified by densitometry from three independent experiments, normalized to levels
of total tau, and plotted as percent phospho-tau in untreated, empty vector/tau transfected cells.
**, p < 0.01 compared with untreated empty vector/tau transfected cells. ##, p < 0.01 compared
with untreated Ckiδ/tau transfected cells.
Fig. 6. CK1 inhibitor IC261 decreases tau phosphorylation. A, stable tau cells were grown to
80% confluence and then incubated with 0, 1, 3, or 10 µM inhibitor IC261 for 30 min. All
reactions were controlled for DMSO, the vehicle for IC261. Treated cells were harvested, lysed,
and subjected to SDS-PAGE. A, representative immunoblots probed with monoclonal antibodies
PHF1, Tau5, and 128A. IC261-mediated inhibition of phospho-tau levels (i.e, PHF1
immunoreactivity) was concentration dependent. B, phospho-tau levels were quantified by
densitometry, normalized to levels of total tau, and plotted as percent inhibition, where 0%
inhibition corresponds to PHF1 immunoreactivity in the absence of IC261. Each point
represents mean ± S.E. of four independent experiments, whereas the line represents best fit of
the data to a rectangular hyperbola ( ). IC261 inhibited tau phosphorylation (PHF1 epitope)
with an IC50 of 1.5 ± 0.5 µM. This value is very similar to the IC50 determined in vitro for Ckiδ
(1.1 ± 0.1 µM; data from Ref. 37; ).
Fig. 7. siRNA decreases tau phosphorylation. Stable tau cells transfected (48 h) with 5 µg of
siRNA selective for Ckiδ or luciferase (GL2) were harvested, lysed, and subjected to SDS-
PAGE (30 µg/lane). A, representative immunoblots probed with monoclonal antibodies PHF1,
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
33
Tau5, and 128A. Treatment with Ckiδ siRNAs decreased levels of Ckiδ and phospho-tau (PHF1
epitope) but not total tau (Tau5 epitope) relative to GL2 control. B, phospho-tau and Ckiδ levels
were quantified by densitometry and plotted as percent GL2 control. Each bar represents the
mean ± S.E. of 3 independent experiments. *, p < 0.05, compared with GL2 control.
Fig. 8. Ckiδ induced tau phosphorylation decreases tau binding to microtubule. A, HEK-
293 cells transiently transfected (24 h) with either a,c, empty vector/tau or b,d, Ckiδ/tau were
harvested and washed with either a,b, PBS or c,d, Microtubule-Stabilizing Buffer. All cells were
then fixed with methanol and immunostained with monoclonal antibody Tau5. a,b, in the
absence of detergent extraction, no change in tau immunofluorescence was observed with Ckiδ
overexpression, showing that transfection of cells with Ckiδ did not change total tau levels. c,d,
in detergent extracted cells, however, expression of Ckiδ led to decreased tau association with
detergent insoluble cytoskeletons. These data are consistent with a migration of tau from
detergent-insoluble to detergent-soluble fractions of the cell in response to Ckiδ overexpression.
B, HEK-293 cells transfected (24 h) with pcDNA/tau or Ckiδ/tau were harvested, lysed, and
separated into soluble (S1) and pellet (P1) fractions by centrifugation as described in
Experimental Procedures. Total (Tau5 epitope), phospho-tau (PHF1 epitope), and α-tubulin
levels were then detected by immunoblot analysis. In pcDNA/tau cells, tau was found
distributed between soluble and particulate fractions. In Ckiδ/tau, however, tau distribution
shifted toward the soluble pool, consistent with a decrease in microtubule association. C, total
tau levels in particulate and soluble fractions were quantified by densitometry. Each bar
represents the mean ± S.E. of 4 independent experiments (**, p < 0.01 compared with empty
vector/tau control). D, microtubule-binding assays were performed using taxol-stabilized
microtubules prepared in vitro and equal volumes of the soluble, cell-derived fractions (S1)
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
34
described above. After centrifugation, the resultant pellet (P2; containing microtubules) and
supernatant (S2) fractions were analyzed for Tubulin by SDS-PAGE (Coomassie blue) and total
tau (Tau5) by immunoblotting. Whereas a portion of soluble tau prepared from cells transfected
with pcDNA/tau was capable of binding microtubules, soluble tau prepared from Ckiδ/tau cells
was almost devoid of microtubule-binding activity.
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from
Guibin Li, Haishan Yin and Jeff KuretCasein kinase 1 delta phosphorylates Tau and disrupts its binding to microtubules
published online February 2, 2004J. Biol. Chem.
10.1074/jbc.M314116200Access the most updated version of this article at doi:
Alerts:
When a correction for this article is posted•
When this article is cited•
to choose from all of JBC's e-mail alertsClick here
by guest on April 4, 2018
http://ww
w.jbc.org/
Dow
nloaded from